Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC203 TIL in advanced gynecologic tumors
NCT05468307Phase 1Completed
- Sponsor
- Juncell Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC203 in gynecologic neoplasms, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Mar 2022; status: completed.
02
Drugs
GC203
03
Conditions
gynecologic neoplasms
Beyond the preview
Go deeper on NCT05468307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468307.